Sun Pharmaceutical Industries growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	+11.2%	+10.0%
EBITDA	+16.1%	+15.0%
Net Income	+5.0%	+10.6%
EPS (adj.)	+5.0%	+10.6%
Total Assets	+18.1%	+10.4%
Total Equity	+15.7%	+12.2%
Free Cash Flow	−26.3%	+45.3%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUNPHARMA₹1,757.50

Sun Pharmaceutical Industries Ltd.

· Pharma & Health

₹ CrorePeersCIPLA DRREDDY LUPIN APOLLOHOSP MAXHEALTH DIVISLAB TORNTPHARM ZYDUSLIFEMcap ₹4.22L Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	+11.2	+10.0
EBITDA	+16.1	+15.0
Net Income	+5.0	+10.6
EPS (adj.)	+5.0	+10.6
Total Assets	+18.1	+10.4
Total Equity	+15.7	+12.2
Free Cash Flow	-26.3	+45.3

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 199%.